Nordic Nanovector ASA – Registered share capital increase
Oslo, 15 December 2014: Reference is made to the general meeting dated 12 November 2014, where it was resolved to pay remuneration to the members of the board of directors by way of cash or in the form of shares to be subscribed to for the nominal value of the shares. The relevant board members as stated in the minutes to the general meeting have subscribed for 17,250 shares.
The share capital increase relating to the issuance of the 17,250 shares has now been registered with the Norwegian Register of Business Enterprises. The new share capital of the Company is NOK 5,302,058.2 divided into 26,510,291 shares, each with a nominal value of NOK 0.2.
Luigi Costa, CEO
Cell: (41) 79 124 8601
Fax: (47) 22 58 00 07
E-mail: lcosta@nordicnanovector.com
Tone Kvåle, CFO
Cell: (47) 91 51 95 76
Fax: (47) 22 58 00 07
E-mail: tkvale@nordicnanovector.com
About Nordic Nanovector ASA
Nordic Nanovector ASA is a privately held company established in 2009. The company is developing innovative radioimmunotherapeutics to treat non-Hodgkin Lymphoma (NHL) and other difficult to treat cancers. Nordic Nanovector intends to commercialise its product candidates through strategic alliances and partnerships with experienced oncology businesses and by establishing its own sales and marketing capabilities in selected markets. The company is based and has offices and laboratories in Oslo, Norway.
The company’s lead product candidate, Betalutin™, is a radioimmunotherapeutic that aims to prolong and improve the quality of life of people who suffer from NHL. Further information can be found at: www.nordicnanovector.com.
Tags:
